Humacyte, Inc.
HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designedā¦ read more
Healthcare
Biotechnology
2 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.72
Price+1.18%
$0.02
1Y
Price
Market Cap
$272.563m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$8.046m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$58.661m
-
1y CAGR-
3y CAGR-
5y CAGREPS
-$0.45
-
1y CAGR-
3y CAGR-
5y CAGRBook Value
$4.052m
$138.795m
Assets$134.743m
Liabilities$15.123m
DebtDebt to Assets
10.9%
-0.4x
Debt to EBITDAFree Cash Flow
-$106.291m
-
1y CAGR-
3y CAGR-
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company